These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18414984)

  • 1. Pulmonary embolism in a patient with multiple myeloma receiving thalidomide-dexamethasone therapy.
    Jeng WJ; Kuo MC; Shih LY; Chu PH
    Int J Hematol; 2008 Jun; 87(5):542-544. PubMed ID: 18414984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
    Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdrè L; Palareti G; Masini L; Tura S; Baccarani M
    Blood; 2002 Sep; 100(6):2272-3. PubMed ID: 12229885
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone].
    Miyazawa Y; Irisawa H; Uchiumi H; Saitoh T; Handa H; Matsushima T; Tsukamoto N; Karasawa M; Murakami H; Nojima Y
    Rinsho Ketsueki; 2006 Jul; 47(7):656-60. PubMed ID: 16910577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
    Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE
    J Clin Oncol; 2002 Nov; 20(21):4319-23. PubMed ID: 12409330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rare complication in a case of multiple myeloma on therapy with thalidomide and dexamethasone--reversible posterior lobe leukoencephalopathy.
    Pandey R; Patel A; Shah S; Patel KM; Shah PM; Shukla SN; Parikh BJ; Anand A; Talati SS; Panchal H; Parikh S; Thrutthel S
    Leuk Lymphoma; 2006 Jul; 47(7):1431-4. PubMed ID: 16923587
    [No Abstract]   [Full Text] [Related]  

  • 7. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.
    Dimopoulos MA; Hamilos G; Zomas A; Gika D; Efstathiou E; Grigoraki V; Poziopoulos C; Xilouri I; Zorzou MP; Anagnostopoulos N; Anagnostopoulos A
    Hematol J; 2004; 5(2):112-7. PubMed ID: 15048060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
    Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G
    Blood; 2001 Sep; 98(5):1614-5. PubMed ID: 11520815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide and dexamethasone: therapy for multiple myeloma.
    Kumar S; Rajkumar SV
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
    Kropff MH; Lang N; Bisping G; Dominé N; Innig G; Hentrich M; Mitterer M; Südhoff T; Fenk R; Straka C; Heinecke A; Koch OM; Ostermann H; Berdel WE; Kienast J
    Br J Haematol; 2003 Aug; 122(4):607-16. PubMed ID: 12899716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
    Baz R; Li L; Kottke-Marchant K; Srkalovic G; McGowan B; Yiannaki E; Karam MA; Faiman B; Jawde RA; Andresen S; Zeldis J; Hussein MA
    Mayo Clin Proc; 2005 Dec; 80(12):1568-74. PubMed ID: 16342649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep venous thrombosis and pulmonary embolism secondary to co-administration of thalidomide and oral corticosteroid in a patient with leprosy.
    Yamaguchi S; Yamamoto Y; Hosokawa A; Hagiwara K; Uezato H; Takahashi K
    J Dermatol; 2012 Aug; 39(8):711-4. PubMed ID: 22373000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial and venous thrombotic complications with thalidomide in multiple myeloma.
    Alkindi S; Dennison D; Pathare A
    Arch Med Res; 2008 Feb; 39(2):257-8. PubMed ID: 18164975
    [No Abstract]   [Full Text] [Related]  

  • 14. Thalidomide and dexamethasone for resistant multiple myeloma.
    Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R
    Br J Haematol; 2003 Jun; 121(5):768-71. PubMed ID: 12780791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
    Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou M; Mitsouli Ch; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A;
    Ann Oncol; 2004 Jan; 15(1):134-8. PubMed ID: 14679133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
    Shah JJ; Stadtmauer EA; Abonour R; Cohen AD; Bensinger WI; Gasparetto C; Kaufman JL; Lentzsch S; Vogl DT; Gomes CL; Pascucci N; Smith DD; Orlowski RZ; Durie BG
    Blood; 2015 Nov; 126(20):2284-90. PubMed ID: 26384354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
    Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G
    Clin Lymphoma; 2003 Jun; 4(1):32-5. PubMed ID: 12837152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
    Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G
    Blood; 2002 Aug; 100(4):1168-71. PubMed ID: 12149193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
    Eo WK; Kim SH; Cheon SH; Lee SH; Jeong JS; Kim YS; Chang HK; Suh KS; Kim HY
    Ann Hematol; 2010 Apr; 89(4):421-2. PubMed ID: 19693501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.